Rare childhood cancers--an increasing entity requiring the need for global consensus and collaboration

Rishi S Kotecha1,2,3, Ursula R Kees3, Catherine H Cole1,2

  • 1Department of Haematology and Oncology, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia, 6840, Australia.

Cancer Medicine
|February 10, 2015
PubMed

Insights

Rare childhood cancers lag behind common cancers in treatment advances. A unified global approach is needed to overcome limitations in current rare tumor research and improve outcomes for all children.

Area of Science:

  • Pediatric Oncology
  • Cancer Research

Background:

  • Rare childhood cancers have seen less progress compared to common cancers.
  • Existing initiatives like tumor groups and registries have improved outcomes but face limitations.
  • Patient numbers and inclusivity remain challenges for current rare cancer research frameworks.

Purpose of the Study:

  • To highlight the need for a more comprehensive approach to studying rare childhood tumors.
  • To address the limitations of current fragmented research efforts in pediatric oncology.

Main Methods:

  • Review of existing strategies for rare childhood cancer research.
  • Analysis of the shortcomings of current patient number and inclusivity limitations.

Main Results:

  • Current approaches, while beneficial, are insufficient for all rare childhood cancers.
  • Fragmented efforts limit the potential for significant breakthroughs.

Conclusions:

  • A single, global, unified approach is essential for advancing the study and treatment of rare childhood tumors.
  • Overcoming current limitations requires international collaboration and a consolidated research strategy.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.6K